<- Go Home
Amarin Corporation plc
Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally through wholesalers, selected regional wholesalers, and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, EPA. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin 2, Ireland.
Market Cap
$166.8M
Volume
1.6M
Cash and Equivalents
$121.0M
EBITDA
-$52.3M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$117.9M
Profit Margin
51.55%
52 Week High
$1.11
52 Week Low
$0.35
Dividend
N/A
Price / Book Value
0.34
Price / Earnings
-2.01
Price / Tangible Book Value
0.35
Enterprise Value
-$117.8M
Enterprise Value / EBITDA
2.38
Operating Income
-$55.3M
Return on Equity
15.83%
Return on Assets
-4.56
Cash and Short Term Investments
$294.2M
Debt
$9.7M
Equity
$486.2M
Revenue
$228.6M
Unlevered FCF
$8.0M
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium